Page 7 - Pharmaceutical Companies

Hospital chains abused their dominance to charge exorbitant prices: Report

A CCI investigation showed that higher pricing was charged for renting rooms, medicines, tests, medical devices, and consumables. In some hospitals, the room rents exceeded charges of 4-star hotels

India sets up export promotion council for medical devices under DoP

India currently exports Rs. 23,766 crore (2021-22) of medical devices up from previous year Rs 19,736 crore

Indian pharma industry eyes South American market, seeks greater access

As Global pharma majors are exiting South America post Covid, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) is looking to promote Indian pharmaceutical exports in the LAC

Paytm shares drop over 6% after ED raid; Blue Jet Healthcare files for IPO

Its stock dropped to an intraday low of Rs 681.2 before closing at Rs 708.6, down 2.6 per cent over its previous day's close

Dolo 650 freebies case: Supreme Court asks Centre to file reply in 10 days

The apex court described the Dolo 650 "freebies case" as a serious matter and listed the next hearing on September 29

Pharma needs a dose of regulation

Code for pharmaceutical marketing must be implemented

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

The recent controversy following income tax raids on Micro Labs, makers of popular paracetamol brand Dolo, is likely to make things move in making the UCPMP

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Lupin revising product portfolio in US to overcome price erosion impact

Homegrown pharmaceutical firm Lupin Ltd is rationalising its product portfolio in the US, transitioning from simple oral solid medicines to more complex generics to overcome the impact of price erosion witnessed in the market, according to the company's CEO Vinita Gupta. With its planned product pipeline for complex generic medicines in the next two years, she said in the years to come the company hopes to have up to 40 per cent of its revenue coming from such medicines in the US market. "...Oral solids (are) still the bread and butter (for the company), but the kind of price erosion one has witnessed on the oral solid side, we decided that it made sense to rationalise the portfolio that does not make sense," she told analysts. Gupta further said, "Whether it's negative margin or low margin, it makes sense to really take the overhead out of our P&L (profit and loss) to improve profitability. We are taking those steps." She was responding to a query on Lupin's strategy to counter ..

Natco Pharma Q1 net profit rises multi-fold to Rs 320 cr on higher revenue

Its consolidated revenue from operations during the quarter under review stood at Rs 884.6 crore compared to Rs 410.3 crore in the same period last fiscal, it added.

BioNTech reports strong H1 with $9.7-bn revenue, expects demand to grow

The German pharmaceutical company said Monday that revenue hit about 9.57 billion euros ($ 9.76 bn) in the first six months of 2022, up from nearly 7.36 billion euros in the same period a year earlier

Sun Pharmaceutical Industries Chairman Israel Makov to retire on Aug 29

Makov is retiring upon the completion of his current term post the company's Annual General Meeting after having led the Mumbai-based company for ten years

Rupee at 80: Neutral impact for India's pharma industry, say experts

India's pharma sector exported drugs worth Rs 1.8 trillion in 2021-22, while APIs worth Rs 30,000 crore were imported

Indian pharma industry may rebound to 8-11% growth rate, says Alkem

Alkem Laboratories expects the Indian pharmaceutical industry to rebound to 8-11 per cent growth rate with normalcy in activities as the pandemic eases out

Biocon Biologics' antibody drug unit in Bengaluru gets EU GMP certificate

Approval comes from Irish health regulator, which had flagged some deficiencies in the manufacturing process iin May

Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts

Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million

Near-term outlook prescription for diagnostic firms looks fragile

Competitive pressures, high valuations limit upsides for listed lab chains

Indoco Remedies gets final nod from US FDA for Lacosamide tablet

Pharmaceuticals firm Indoco Remedies Ltd on Tuesday said it has received final approval from the US health regulator for its generic Lacosamide tablet indicated for prevention and control of seizures. The approval granted by the US Food & Drug Administration (USFDA) for Lacosamide tablets is for strengths of 50 mg, 100 mg, 150 mg and 200 mg. These are the generic version of Vimpat Tablets of UCB Inc, the company said in a regulatory filing. Indoco Remedies Managing Director Aditi Kare Panandikar said, "The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates our enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Our first shipment of Lacosamide tablets has already reached the US". Lacosamide tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug, the company said. Citing IQVIA sales data for the period ending January 2022, the company ..

Macleods Pharmaceuticals recalls products in US for manufacturing issues

Macleods Pharmaceuticals is recalling two products in the US market due to deviation from standard manufacturing norms, according to a USFDA report.

Pharma industry likely to grow to $130 billion by 2030: Industry leaders

'As India becomes an increasingly more important component for the global supply chain, that should benefit the industry going forward,' Sun Pharma Managing Director Dilip Shanghvi said